Omega Healthcare Investors has delivered a strong 115.8% total return over the past five years, and the latest valuation work suggests the stock may still trade below an estimate of intrinsic value based on Discounted Cash Flow, rather than looking stretched after that run.

• A 115.8% return over five years suggests long term holders in Omega Healthcare Investors have already been well rewarded. Any further upside case now rests on whether the current price still leaves a margin against intrinsic value.
• The recent decision to increase the quarterly dividend can support the investment case if higher funds available for distribution continue. Any setback in operating growth could challenge the current valuation.
• Omega Healthcare Investors screens as undervalued across several checks, yet a value score of 4 out of 6 points to a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether the current share price of Omega Healthcare Investors still offers a reasonable discount to intrinsic value after its multi year gains.

Is Omega Healthcare Investors Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here projects what Omega Healthcare Investors could generate for shareholders based on future adjusted funds from operations. On the latest twelve month numbers the model uses free cash flow of about $946.2 million and assumes those cash flows continue to grow rather than shrink over time. That cash stream, discounted back using a two stage approach, produces an estimated intrinsic value of about $95.90 per share.

Compared with the current share price, this implies the stock trades at roughly a 46.4% discount and screens as undervalued. The recent decision to lift the quarterly dividend, backed by higher funds available for distribution, provides some support for the cash flow profile that underpins this DCF result.

On this DCF view, Omega Healthcare Investors stock appears undervalued relative to the cash flows currently included in the model.

Our Discounted Cash Flow (DCF) analysis suggests Omega Healthcare Investors is undervalued by 46.4%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Is Omega Healthcare Investors a Bargain on Earnings?

The P/E ratio works well for Omega Healthcare Investors because earnings are a key anchor for how income focused investors look at this REIT. Omega Healthcare Investors currently trades on a P/E of 24.8x, which sits above the Health Care REITs industry average of 19.3x yet well below the broader peer average near 62.0x.

The tailored fair P/E ratio for Omega Healthcare Investors is 33.1x based on factors such as size, risk and earnings profile. That fair level is higher than the current 24.8x, which indicates the stock screens as undervalued on this metric even though it carries a premium to the industry average. In other words, the market is pricing Omega below where this framework would place it, given its specific characteristics.

On the P/E multiple alone, Omega Healthcare Investors stock appears undervalued relative to the fair ratio implied by its fundamentals and risk profile.

The Omega Healthcare Investors Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Omega Healthcare Investors valuation work leaves off and set out what would need to be true about the company’s future to justify a much higher or lower share price. Each one turns fair value into a clear thesis about Omega Healthcare Investors' business that you can revisit over time, and they sit on Simply Wall St's Community page for ongoing reference.

You can be one of the first voices in the Simply Wall St community to set out a clear, number driven Narrative on Omega Healthcare Investors, including a view on whether the recent quarterly dividend increase to US$0.68 per share ultimately delivers for shareholders. Share your thesis now so you can track how it holds up as new results and updates arrive.

Do you think there's more to the story for Omega Healthcare Investors? Head over to our Community to see what others are saying!

The Bottom Line

Omega Healthcare Investors screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and on its tailored P/E multiple, which points to some valuation support even after a strong five year run. The broader checks are mixed rather than overwhelmingly positive, so the current discount is not a free pass and could also reflect ongoing risks around operating performance and distributions. The key question from here is whether Omega Healthcare Investors can sustain the cash flow and earnings profile that these models assume. That will decide whether the present discount represents genuine value or a reasonable cushion for those risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.